{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:49:13Z","timestamp":1761569353026,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCT00445601"],"award-info":[{"award-number":["NCT00445601"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clgc.2022.06.015","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T02:04:38Z","timestamp":1656122678000},"page":"e498-e505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis"],"prefix":"10.1016","volume":"20","author":[{"given":"Nicholas J.","family":"Corsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward M.","family":"Messing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Keeley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandler","family":"Bronkema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Rakic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepansh","family":"Dalela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohrab","family":"Arora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-6545","authenticated-orcid":false,"given":"Austin J.","family":"Piontkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami E.","family":"Majdalany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Butaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Rakic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mani","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig G.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1298-8231","authenticated-orcid":false,"given":"Firas","family":"Abdollah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2022.06.015_bib0001","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"issue":"6 Suppl 1","key":"10.1016\/j.clgc.2022.06.015_bib0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.clgc.2022.06.015_bib0003","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0094-0143(03)00060-0","article-title":"Evaluation and follow-up strategies for superficial bladder cancer","volume":"30","author":"Donat","year":"2003","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.clgc.2022.06.015_bib0004","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.urology.2017.07.016","article-title":"The burden of cystoscopic bladder cancer surveillance: anxiety, discomfort, and patient preferences for decision making","volume":"108","author":"Koo","year":"2017","journal-title":"Urology"},{"issue":"18","key":"10.1016\/j.clgc.2022.06.015_bib0005","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.clgc.2022.06.015_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2022.06.015_bib0007","doi-asserted-by":"crossref","first-page":"198.e1","DOI":"10.1016\/j.clgc.2021.11.016","volume":"20","author":"Del Giudice","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2022.06.015_bib0008","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.juro.2018.06.019","article-title":"Can we improve nonmuscle invasive bladder cancer guideline adherence with smarter risk stratification?","volume":"200","author":"Downs","year":"2018","journal-title":"J Urol"},{"issue":"23","key":"10.1016\/j.clgc.2022.06.015_bib0009","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1002\/cncr.26198","article-title":"Compliance with guidelines for patients with bladder cancer: variation in the delivery of care","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.clgc.2022.06.015_bib0010","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of Intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clgc.2022.06.015_bib0011","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2307\/2531894","article-title":"Regression trees for censored data","volume":"44","author":"Segal","year":"1988","journal-title":"Biometrics"},{"issue":"6","key":"10.1016\/j.clgc.2022.06.015_bib0012","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1464-410X.2012.11560.x","article-title":"A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy","volume":"111","author":"Abdollah","year":"2013","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.clgc.2022.06.015_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2022.06.015_bib0014","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.juro.2011.12.056","article-title":"National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer","volume":"187","author":"Cookson","year":"2012","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.clgc.2022.06.015_bib0015","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00345-018-2591-1","article-title":"Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what","volume":"37","author":"Peyton","year":"2019","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2022.06.015_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non-muscle-invasive bladder cancer among older adults, 2004-2013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.clgc.2022.06.015_bib0017","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.euf.2018.07.032","article-title":"Predicting Response to intravesical therapy in non-muscle-invasive bladder cancer","volume":"4","author":"Alameddine","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.clgc.2022.06.015_bib0018","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/bjc.2013.372","article-title":"Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder","volume":"109","author":"Xylinas","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2022.06.015_bib0019","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/0970-1591.166445","article-title":"Non-muscle invasive bladder cancer risk stratification","volume":"31","author":"Isharwal","year":"2015","journal-title":"Indian J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2022.06.015_bib0020","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.juro.2017.04.077","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in a united states population","volume":"198","author":"Ravvaz","year":"2017","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2022.06.015_bib0021","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12894-019-0530-0","article-title":"Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Urol"},{"issue":"3","key":"10.1016\/j.clgc.2022.06.015_bib0022","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.euf.2018.11.005","article-title":"Risk stratification tools and prognostic models in non-muscle-invasive bladder cancer: a critical assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel","volume":"6","author":"Soukup","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.clgc.2022.06.015_bib0023","article-title":"The evaluation of the risk factors for non-muscle invasive bladder cancer (NMIBC) recurrence after transurethral resection (TURBt) in Chinese population","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.clgc.2022.06.015_bib0024","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1200\/JCO.2005.11.136","article-title":"Improved detection of prostate cancer using classification and regression tree analysis","volume":"23","author":"Garzotto","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:37:05Z","timestamp":1761565025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322001409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1558767322001409"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.06.015","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}